Research Paper Volume 12, Issue 17 pp 17662—17680

Figure 6. AntagomiR-mediated inhibition of miR-92a-1-5p in vivo reduces CML xenograft growth. (A) K562 xenografts were established in NOD/SCID mice injected intratumorally with antagomiR-92a-1-5p (8 nmol/d, 25 μL), antagomiR-NC (8 nmol/d, 25 μL), or PBS (25 μL/d, as control) every other day for 2 weeks (n = 4 mice/group). Tumor volumes and mouse weights were measured at the indicated time points. Data are presented as the mean ± SD. **p < 0.01. (B) Photographs of excised K562 tumors and corresponding weight measurements. **p < 0.01. (C) ISH detection of miR-92a-1-5p expression in excised tumors and integrated optical density (IOD) quantification (mean ± SD; **p < 0.01). (D) IHC analysis of MLKL expression in excised tumors and IOD quantification (mean ± SD; **p < 0.01).